VHL and pancreatic neuroendocrine tumor: It is noteworthy that the HIF-2α inhibitor belzutifan represents a novel promising non-interventional option for inherited VHL-related pancreatic NETs, and has already been FDA-approved for renal cell carcinoma [40].